Comparison of a Hand-held Nebulizer with a Metered Dose Inhaler-Spacer Combination in Acute Obstructive Pulmonary Disease (9)

Comparison of a Hand-held Nebulizer with a Metered Dose Inhaler-Spacer Combination in Acute Obstructive Pulmonary Disease (9)These statistically significant improvements in FVC were present whether the two subjects with bronchitis were combined with the COPD patients or not. Eight of ten asthmatic subjects showed a greater than 15 percent improvement in FEV, after HHN but only one of ten demonstrated this level of improvement after MDI-spacer. In one of five COPD subjects and one bronchitis subject, a 15 percent improvement in FEV, was achieved after use of either mode of administration.
The comparison of the spirometry before and after metaproterenol delivered by MDI-spacer and HHN is shown in Table 1. There was a statistically significant improvement in FVC and FEV, after metaproterenol delivered by HHN, but not after MDI-spacer, for the combined group of all 17 subjects and for the subgroup of subjects with asthma. The subgroup of COPD subjects demonstrated a significant improvement in FVC only after HHN. This increase in FVC after metaproterenol delivered by HHN remained statistically significant whether the two subjects with bronchitis were combined with the COPD patients or the five COPD episodes were analyzed independently. All of the subjects exhibited wheezing during the study period. An improvement in the wheezing was noted on lung auscultation in 12 of the 17 subjects after HHN, and in 10 of the 17 subjects after MDI-spacer.